<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897597</url>
  </required_header>
  <id_info>
    <org_study_id>1313.9</org_study_id>
    <secondary_id>2013-000258-23</secondary_id>
    <nct_id>NCT01897597</nct_id>
  </id_info>
  <brief_title>Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions</brief_title>
  <official_title>An Open-label, Single Dose, Randomised, Crossover Trial in Healthy Male Subjects to Investigate the Relative Bioavailability of Tablet and Oral Solution of Two Doses of BI 144807 and Relative Bioavailability of BI 144807 When Administered as Tablet Under Fed and Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the relative bioavailability of a BI 144807
      tablet formulation compared to the oral solution formulation after single dose administration
      (intermediate and high dose) under fasted conditions. Further objectives are to assess
      whether and to what extent food affects single dose pharmacokinetics of BI 144807
      administered as tablet, and to compare the relative bioavailability of two different tablet
      formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 144807 PfoS Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermediate dose of BI 144807</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 144807 PfoS Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of BI 144807</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 144807 Tab Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermediate dose of BI 144807</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 144807 Tab Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of BI 144807</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 144807 Tab Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermediate dose of BI 144807, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 144807 Tab Treatment F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermediate dose of BI 144807, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 144807 Tab Treatment G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermediate dose of BI 144807, fasted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 144807 high dose</intervention_name>
    <description>oral solution</description>
    <arm_group_label>BI 144807 PfoS Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 144807 intermediate dose</intervention_name>
    <description>tablet</description>
    <arm_group_label>BI 144807 Tab Treatment F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 144807 intermediate dose</intervention_name>
    <description>tablet</description>
    <arm_group_label>BI 144807 Tab Treatment E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 144807 intermediate dose</intervention_name>
    <description>tablet</description>
    <arm_group_label>BI 144807 Tab Treatment G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 144807 intermediate dose</intervention_name>
    <description>tablet</description>
    <arm_group_label>BI 144807 Tab Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 144807 intermediate dose</intervention_name>
    <description>oral solution</description>
    <arm_group_label>BI 144807 PfoS Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 144807 high dose</intervention_name>
    <description>tablet</description>
    <arm_group_label>BI 144807 Tab Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Healthy male subjects

        Exclusion criteria:

        - Any relevant deviation from healthy condition
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1313.9.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

